Table 3B.
CD8 subsets by study arm—adjusted analysis.
| Visits | |||||||
|---|---|---|---|---|---|---|---|
| Adjusted means | Adjusted difference in means | ||||||
| Markers | |||||||
| T0 95% CI |
T6 95% CI |
T12 95% CI |
T0 95% CI p-Value |
T6 95% CI p-Value |
T12 95% CI p-Value |
p-Value* | |
| CD8 TM, cells/mm3 | |||||||
| RCT arm | 0.086 | ||||||
| DTG/3TC | 83.7 (61.5, 106.0) | 92.3 (70.1, 114.5) | 78.8 (56.7, 100.9) | 0 | 0 | 0 | |
| B/F/TAF | 87.8 (64.2, 111.4) | 80.0 (56.4, 103.6) | 86.8 (63.0, 110.7) | 4.1 (−29.4, 37.5) | −12.3 (−45.8, 21.2) | 8.0 (−25.6, 41.6) | |
| 0.812 | 0.473 | 0.640 | |||||
| CD8 EMRA, cells/mm3 | |||||||
| RCT arm | 0.186 | ||||||
| DTG/3TC | 351.2 (254.7, 447.6) | 364.6 (268.2, 461.0) | 349.4 (253.1, 445.6) | 0 | 0 | 0 | |
| B/F/TAF | 350.2 (247.3, 453.0) | 314.7 (211.8, 417.6) | 336.2 (232.9, 439.5) | −1.0 (−147, 145.2) | −49.9 (−196, 96.3) | −13.2 (−160, 133.3) | |
| 0.990 | 0.505 | 0.860 | |||||
| CD8 CD57 PD1, cells/mm3 | |||||||
| RCT arm | 0.160 | ||||||
| DTG/3TC | 14.7 (9.1, 20.2) | 19.0 (13.5, 24.6) | 20.1 (14.6, 25.6) | 0 | 0 | 0 | |
| B/F/TAF | 16.1 (10.2, 22.0) | 15.9 (10.0, 21.8) | 20.3 (14.4, 26.3) | 1.4 (−6.9, 9.8) | −3.1 (−11.5, 5.2) | 0.2 (−8.1, 8.6) | |
| 0.739 | 0.461 | 0.955 | |||||
| CD8 subsets (change) by study arm—adjusted analysis. | |||||||
| Visits | |||||||
| Adjusted mean changes from T0 | Adjusted difference in mean changes from T0 | ||||||
| Markers | |||||||
| T0 95% CI |
T6 95% CI |
T12 95% CI |
T0 95% CI p-Value |
T6 95% CI p-Value |
T12 95% CI p-Value |
p-Value* | |
| CD8 TM, cells/mm3 | |||||||
| RCT arm | 0.212 | ||||||
| DTG/3TC | −0.3 (−9.0, 8.3) | 3.6 (−5.1, 12.3) | −0.2 (−8.7, 8.4) | 0 | 0 | 0 | |
| B/F/TAF | 0.4 (−8.8, 9.5) | −3.1 (−12.3, 6.0) | 6.1 (−3.2, 15.4) | −6.7 (−19.6, 6.1) | 6.3 (−6.6, 19.2) | ||
| 0.306 | 0.341 | ||||||
| CD8 EMRA, cells/mm3 | |||||||
| RCT arm | 0.673 | ||||||
| DTG/3TC | 2.2 (−21.3, 25.6) | −0.7 (−24.3, 22.8) | 23.3 (0.1, 46.5) | 0 | 0 | 0 | |
| B/F/TAF | −2.6 (−27.4, 22.1) | −19.2 (−44.0, 5.5) | −2.3 (−27.6, 23.0) | −18.5 (−53.3, 16.3) | −25.6 (−60.6, 9.4) | ||
| 0.299 | 0.155 | ||||||
| CD8 CD57 PD1, cells/mm3 | |||||||
| RCT arm | 0.200 | ||||||
| DTG/3TC | −0.1 (−3.0, 2.8) | 4.1 (1.2, 7.0) | 6.3 (3.4, 9.2) | 0 | 0 | 0 | |
| B/F/TAF | 0.1 (−3.0, 3.2) | −0.0 (−3.1, 3.0) | 4.0 (0.8, 7.1) | −4.1 (−8.5, 0.2) | −2.3 (−6.7, 2.0) | ||
| 0.064 | 0.299 | ||||||
* F-test type 3 interaction p-value.
& Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD4 count nadir.
RCT, randomized clinical trial; VL, viral load.
* F-test type 3 interaction p-value.
& Adjusted for age, nationality, AIDS, duration of HIV, duration of VL suppression, and CD8 count nadir.